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Abstract
Background Regular colonoscopic surveillance for detection
of dysplasia is recommended in longstanding inflammatory
bowel disease (IBD), however, its sensitivity is disputed.
Screening accuracy may increase by using a biomarker-based
surveillance strategy.
Methods A case-control study was performed to determine
the prognostic value of DNA ploidy and p53 in IBD-related
neoplasia. Cases with IBD-related colorectal cancer (CRC),
detected in our surveillance program between 1985-2008,
were selected and matched with two controls, for age,
gender, disease characteristics, interval of follow-up, PSC,
and previous surgery. Biopsies were assessed for DNA
ploidy, p53, grade of inflammation and neoplasia. Progression
to neoplasia was analyzed with Cox regression analysis,
adjusting for potentially confounding variables.
Results Adjusting for age, we found statistically significant
Hazard ratios (HR) between development of CRC, and low
grade dysplasia (HR5.5; 95%CI 2.6-11.5), abnormal DNA
ploidy (DNA index (DI) 1.06-1.34, HR4.7; 95%CI 2.9-7.8
and DI>1.34, HR6.6; 95%CI 3.7-11.7) and p53 immunopo-
sitivity (HR3.0; 95%CI 1.9-4.7) over time. When adjusting
for all confounders, abnormal DNA ploidy (DI 1.06-1.34,
HR4.7; 95%CI 2.7-7.9 and DI>1.34, HR5.0; 95%CI 2.5-10.0)
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and p53 immunopositivity (HR1.7; 95%CI 1.0-3.1) remained
statistically significant predictive of neoplasia.
Conclusion In longstanding IBD, abnormal DNA ploidy and
p53 immunopositivity are important risk factors of developing
CRC. The yield of surveillance may potentially increase by
adding these biomarkers to the routine assessment of biopsies.
Keywords Inflammatory bowel disease . Colorectal
cancer . Surveillance . Abnormal DNA ploidy . p53
immunopositivity
1 Introduction
Inflammatory bowel disease (IBD), which includes ulcera-
tive colitis (UC) and Crohn’s disease (CD), is a chronic
inflammatory disorder of the intestine. With approximately
4 million patients affected in the Western world, IBD is one
of the most common chronic inflammatory disorders.
Epidemiological evidence indicates that patients with IBD
are at increased risk of developing colorectal cancer (CRC).
The risk is considerable as it has been estimated that up to
one in five patients will develop CRC within 30 years after
an initial diagnosis of IBD [9].
Duration of the disease is a major clinical risk factor for
IBD-related CRC, with a relative risk with long-standing
colitis increasing to 6–18 [6, 7]. Most IBD-related CRC is
seen in patients with pancolitis, whereas proctitis and left-
sided colitis are associated with a small to intermediate
cancer risk. Other risk factors for IBD-related CRC include
young age at onset of IBD, presence of primary sclerosing
cholangitis, presence of pseudopolyps, and a positive
family history for CRC [1, 6, 7, 19].
Current guidelines from the American Gastroenterology
Association (AGA) [2] and the British Society of Gastro-
enterology (BSG) [4, 8] recommend colonoscopic surveil-
lance every 1 to 5 years for IBD-colitis patients starting 8 to
10 years after the initial diagnosis. This surveillance aims at
early detection of neoplastic lesions, at a treatable stage [6].
Detection of dysplasia is generally accepted as the gold
standard to predict cancer risk. Dysplasia as risk predictor
for IBD-related cancer is however known to have signifi-
cant shortcomings.
Dysplasia, which is commonly sub classified into two
distinct morphological stages, i.e., low-grade dysplasia
(LGD) and high-grade dysplasia (HGD), often arises
multifocally throughout the colon of IBD patients. As
dysplastic lesions are difficult to recognize by conventional
endoscopy, the obtained biopsy specimens are prone to
sampling error [18, 33]. In addition, misinterpretation of
dysplasia occurs due to inter- and intraobserver variability
between pathologists, and by the co-existent presence of
variable degrees of inflammation [9, 26, 33].
In the search of better markers for the prediction of IBD-
related CRC development, a variety of biomarkers have
been studied, including DNA ploidy, and mutations of the
APC gene, K-ras gene, DCC gene and p53 tumor
suppressor gene [5, 18]. Of these, DNA ploidy and p53
gene mutations currently seem to be the most promising
candidates [5, 16, 18, 25, 34]. Both markers are observed
early during the cascade of CRC development and, in
addition, they are assumed to be diffusely expressed thus
decreasing the risk of sampling error [21, 22].
As the relative risk of abnormal DNA ploidy and p53
immunopositivity in developing IBD-related CRC is currently
unknown, we investigated the prognostic value of these
markers for neoplastic progression in a case–control study
design by testing surveillance biopsies of high-risk IBD
patients (biopsy specimens taken ≥8 years after the diagnosis
of IBD), who either or not progressed towards CRC.
2 Materials and methods
2.1 Patients selection
This retrospective case–control study was conducted in the
IBD patient cohort of the Erasmus MC, Rotterdam, the
Netherlands. Cases were high-risk IBD patients with docu-
mented neoplastic progression (defined as patients with
progression to CRC). Each case was preferentially matched
with two controls. Controls were IBD-colitis patients without
signs of neoplastic progression (defined as patients without
HGD or CRC) during surveillance. Cases and controls were
matched for age (with a maximum of 2 years difference),
gender, colitis characteristics (i.e. extension and underlying
UC or CD), age at onset of colitis symptoms, disease duration,
interval of follow-up since the first colonoscopy (with a
maximum of 1 year difference), presence of PSC, and
previous surgery. Inclusion criteria for cases were (i) IBD
history ≥8 years; (ii) confirmed IBD by colonoscopy and
histology; and (iii) having undergone at least one surveillance
colonoscopy with biopsy sampling prior to the development
of neoplasia. An exclusion criterion was IBD with dysplasia
or CRC at the first colonoscopy.
Biopsies specimens collected at routine surveillance
colonoscopies or colectomy between 1985 and 2008 in
our institute were retrieved and analyzed for histology,
DNA ploidy and p53 as described below. They consist of
1,671 samples obtained from different locations of the
colon and originated from 54 unrelated patients. Use of
patient material was approved by the Medical Ethical
Committee of the Erasmus MC.
Since 2001, a standardized biopsy protocol was used
(four-quadrant biopsy specimens every 10 cm). Before
2001, the biopsy protocol was not standardized.
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2.2 Histology
Formalin-fixed paraffin-embedded tissue samples were
serially sectioned at 4 or 50 μm. The first and last
section 4 μm were stained with hematoxylin & eosin stain
and light microscopically evaluated. The degree of inflam-
mation and dysplasia grade or presence of CRC was
reevaluated by one expert gastrointestinal pathologist
without knowledge of clinical and biomarker status, using
the Geboes scoring system [10] and the International
Classification of Dysplasia in Inflammatory Bowel Disease
[29]. Patients were classified according to the most severe
abnormality present in the biopsy specimens.
2.3 DNA ploidy by flow cytometry
DNA ploidy analysis was performed on formalin-fixed
paraffin-embedded biopsy specimens using a pepsinization
technique, which was modified from Hedley et al. [15]. For
each sample, one 50-μm-thick section was obtained from
the paraffin block. Following deparaffinization in xylene
and subsequent rehydration. The tissue was suspended in
phosphate-buffered-saline (PBS). Then, the specimens were
incubated in 0.05% protease (Sigma-Aldrich, Zwijdrecht,
The Netherlands) for 45 min at 37°C, minced mechanically
with a syringe and a 60-μm needle, and filtered through a
50-μm nylon mesh. Subsequently, the suspension was
centrifuged for 10 min at 900 g, the supernatant was
discarded and the pellet was resuspended in PBS containing
0.01% RNAse (Simga-Aldrich). For DNA staining, 0.01%
propidium iodide was added to the samples. At least
10,000–15,000 nuclei per specimen were analyzed by
FACScan flow cytometry (Becton Dickinson, San Jose,
CA). Data analysis was performed using CellQuest (Becton
Dickinson) and Modfit 3.1 software packages (Verity
Software House, Inc, Topsham, ME, USA). The DNA
index (DI) was calculated as the ratio of the abnormal G0/G1
mean peak channel number to the normal diploid G0/G1
mean peak channel number. Histograms displaying a G0/G1
peak with a coefficient of variation (CV) of 1%≤CV≤10%
were included in the analysis. Samples were considered
diploid when the DNA index was 0.95≤DI≤1.05, near
diploid in case of 1.06≤DI≤1.34, and aneuploid in case of
a DI >1.34 [11, 32]. DNA histograms were classified
without knowledge of the histological diagnosis.
2.4 p53 immunohistochemistry
Immunohistochemistry for p53 was performed on 4 μm
formalin-fixed paraffin-embedded tissue slide. After depar-
affinization in xylene and rehydration through graded ethanol,
the sections were incubated with 3% H2O2 in methanol for
10 min. Then, the section were microwaved in monocitric
acid buffer pH 6.0 for 20 min, washed, and blocked with
10% normal human plasma, 10% goat serum (Dako-
cytomation, Heverlee, Belgium) and 5% bovine serum
albumin (Sigma-Aldrich) in Tris–HCl pH 9.0. p53 immu-
nostaining was accomplished using a mouse monoclonal
antibody, i.e. clone DO-7 (1:100, Dako-cytomation). After
overnight incubation with DO-7 at 4°C, p53 signals were
amplified with Envision (Dako-cytomation). Subsequently,
3′-3′-diaminobenzidine (1 g/L, Sigma-Aldrich) was added to
the slide to detect p53. The slides were counterstained in
Harris’ hematoxylin, dehydrated and mounted. To determine
the intraobserver variability between the different experi-
ments, control slides (n=3) of tissue that previously had
shown to express p53 were included in the experiments.
When the results of control slides differed from the results of
previous staining, data were excluded from the analysis and
the experiment was repeated. Substitution of the primary
antibody by IgGb2 (Dako-cytomation) or Tris–HCl pH 9.0 in
a matched serial section was used as a negative control. The
intensity and percentage of positive cells were evaluated by
two experts without knowledge of clinical and DNA ploidy
status. Overexpression of p53 was defined as moderate and
intense brown staining in >15% of the nuclei [14].
2.5 Statistical analysis
Statistical analyses were conducted using SPSS software
(SPSS version 16.0, Chicago, Illinois, USA) and R
software (R foundation for Statistical Computing, version
2.6.2).
Median and 25–75 percentiles were calculated for all
continuous variables while proportions were calculated for
all categorical variables.
At each follow-up visit (colonoscopies performed on
regular basis ≥8 years after the diagnosis of IBD),
histology, expression of the biomarkers, and grade of
inflammation were determined in biopsy specimens taken
from different locations of the colon of the same patient.
For the analysis, we used from each time point the biopsy
that was most different from normal (e.g. if for one patient
at one time point one biopsy was aneuploid, one near
diploid and three diploid, that time point was scored
aneuploid).
To estimate the predictive value of histology, DNA ploidy,
p53 and grade of inflammation we used Cox proportional
hazard regression with time dependent covariates to take the
multiple time points per patient into account. The relationship
between these predictors and IBD-related neoplasia was
expressed in hazard ratios (HR) with 95% confidence
intervals (CI). We first adjusted for age, then for age and
LGD and finally for the complete set of confounders (age,
LGD, DNA ploidy, p53 immunopositivity and grade of
inflammation).
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Random effect regression analysis was used to calculate
the statistical significance level of the correlation between
outcome and the different predictors. This model takes the
dependency between biopsy specimens per follow-up visit
per patient into account. The data is presented by grade of
neoplasia. P-values <0.05 were considered statistically
significant. Smoothing splines were used to visualize trends
over time for the biomarkers, DNA ploidy and p53
immunopositivity.
3 Results
3.1 Patient characteristics
In our cohort of IBD patients who underwent colonoscopic
surveillance at the Erasmus MC—Rotterdam between 1985
and 2008, 36 patients developed CRC. Sixteen patients were
excluded from the study because of an IBD history <8 years,
HGD or CRC at their first surveillance colonoscopy, or lack of
surveillance biopsies. For the twenty remaining IBD cases
(CD, n=8; UC, n=12), 844 biopsy specimens, with a median
(25–75 percentiles) of 6.0 (4.0–10.0) biopsies per colono-
scopy or colectomy, were analyzed. 730 biopsy specimens
had been taken prior to the development of HGD and/or
CRC, and 171 specimens at the time of HGD and/or CRC.
Cases were matched with 34 controls (CD, n=14; UC, n=
20). From these, in total 827 biopsy specimens obtained
during colonoscopic surveillance or colectomy were included.
For six cases (CD, n=2; UC, n=4), no second matched
control fulfilling all selection criteria could be selected from
our patient cohort.
All patients’ characteristics are given in Table 1. No
significant differences were observed between the cases and
controls in age, gender, disease characteristics, interval of
follow-up, treatment during surveillance, family history,
PSC, and previous surgery.
During surveillance, ten colectomies were recommended
for reasons of dysplasia (all cases), and six as a result of
severe colitis (cases, n=2; controls, n=4). One patient with
LGD refused to undergo surgery. In seven of the nine
colectomies after a previous biopsy-based diagnosis of
Table 1 Characteristics of inflammatory bowel disease (IBD) patients
Variables Cases (n=20 patients) Controls (n=34 patients) p-value
Age at IBD diagnosis, y 25.3 (19.2–38.4) 25.8 (18.9–34.8) 0.6
Male, n 20 (75.0%) 24 (70.6%) 0.7
IBD history, y 17.0 (12.0–23.8) 18.5 (14.0–23.3) 0.7
Follow-up period, y 8.0 (1.3–11.5) 7.2 (2.2–12.6) 0.8
Colonoscopies/follow-up period, n 4.4 (1.5–7.0)a 4.3 (2.0–5.3) 0.8
Interval between follow-up colonoscopies, y 1.6 (0.6–2.3)a 2.0 (1.0–2.4) 0.04
Total number of follow-up visits 116 148 –
Type of colitis, n 0.2
Proctitis 3 (15.0%) 1 (2.9%)
Left-sided colitis 3(15.0%) 12 (35.3%)
Pancolitis 14 (70.0%) 20 (58.8%)
Right-sided colitis – 1 (2.9%)
Positive family history, n 2 (10.0%) 4/34 (11.8) 0.8
Primary sclerosing cholangitis, n 6 (30.0%) 6 (17.6%) 0.3
Medication use 18 (90.0%)b 34 (100%)
Aminosalicylates, n 15 (83%) 31 (91%) 0.4
Corticosteroids, n 11 (61%) 21 (62%) 1.0
Immunosuppressives, n 7 (38%) 11 (32%) 0.6
Biologicals, n 2 (11%) 2 (6%) 0.5
Surgery during surveillance, n 5 (25.0%) 4 (11.4%) 0.2
Total number of biopsies, n 844 827 –
Biopsies per colonoscopy 6.0 (4.0–10.0) 5.6 (3.0–7.0) 0.08
a Prior to the development HGD and/or CRC
b Information on medication use of two patients was missing
y, years; n, number
Median (25–75 percentiles) given for continuous variables
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dysplasia, HGD and/or CRC lesions were detected by the
pathologist. No sign of neoplasia were seen in the
colectomies of the patients with severe colitis. All patients
without histological conformation of HGD or CRC continued
the surveillance program.
3.2 Histology
Grading surveillance biopsies according to the International
Classification of Dysplasia in Inflammatory Bowel Disease
[29] revealed that the majority of specimens (1123/1671;
67.2%) exhibited no dysplasia (ND). Biopsy specimens of
one follow-up visit of the cases could not be graded due to
severe architectural changes. When the specimens were
analyzed per follow-up visit (Fig. 1a), ND was seen in
53.0% (61/115) of the follow-up visits in the cases,
compared to 87.8% (130/148) in the controls. Indefinite
dysplasia (IND) was found in 16.5% (19/115) and 11.5%
(17/148), respectively. LGD was detected in 7.8% (9/115)
of the follow-up visits in the cases, compared to 0.7% (1/148)
in the controls. HGD and CRC were detected in 5.2% (6/115)
and 17.4% (20/115) of the follow-up visits in cases, compared
to none in controls.
By endoscopy and macroscopy examination of the colon
after colectomy, 80% (29/36) of the abnormal lesions were
seen. Seventeen lesions were raised. Four lesions with
dysplasia (LGD n=3, HGD=1) were missed by the endo-
scopists and were only detected histologically. For three
lesions, the data on morphology of the lesion was missing.
When comparing the different specimens obtained from a
single patient at a single time point, we found that 41.6% (14/
36) of the sample-sets displayed differences in the grading
between the individual samples from that particular time
point. In most of these cases (n=9), HGD and CRC at one
spot was accompanied by LGD or HGD at another spot. At
five time points, biopsy specimens with neoplasia were
b
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Fig. 1 Prevalence of neoplasia and inflammatory activity in different
IBD subgroups. a Percentages of follow-up visits with neoplasia
graded according to the International Classification of Dysplasia in
Inflammatory Bowel Disease [29] in the case and control group.
Biopsy specimens of one follow-up visit of the cases could not be
graded due to severe architectural changes. P-value from random
effect regression analyses for difference between the cases and
controls in grade of neoplasia is p=0.7 for IND, p=0.8 for LGD,
p=1.00 for HGD and p=1.00. In the ND-group this analysis revealed
p-value of p=0.8 for IND. ND has been used as reference conditions.
b Inflammatory activity graded according to the Geboes scoring
system [10] in different subgroups of IBD patients. Biopsy specimens
of eight follow-up visits of the cases could not be graded due to severe
architectural changes or limited amount of tissue (IND n=1, CRC n=
7). P-value from random effect regression analyses for difference
between the cases and controls in inflammatory activity are p=0.8 for
mild colitis, p=0.7 for moderate colitis and p=0.7 for severe colitis. In
the ND-group the same analysis revealed p-values of p=0.9, p=0.7
and p=0.8, respectively. Inactive colitis has been used as reference
conditions. Normal, ND, no dysplasia; IND, indefinite dysplasia;
LGD, low grade dysplasia; HGD, high grade dysplasia; CRC,
colorectal cancer (CRC). Mild colitis, neutrophil infiltration of <50%
with no crypt destruction, erosion or ulceration; moderate colitis,
neutrophil infiltration of >50% with no erosion or ulceration; severe
colitis, erosion or ulceration
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found together with biopsy specimens without neoplasia (no
LGD, HGD and CRC). As 66% (10/15) the colonoscopies
were performed before the standardized biopsy protocol of
2001, data on the exact location of the biopsy is scarce.
We also graded the surveillance biopsies according to the
Geboes scoring system [10]. Biopsy specimens of eight
follow-up visits of the cases could not be graded due to
severe architectural changes or limited amount of tissue
(IND n=1, CRC n=7). Moderate colitis was more often
seen in cases per follow-up visit than in controls, even
before LGD, HGD and/or CRC occurred (Fig. 1b).
When comparing the sample-sets from a single patient at
a single time point with neoplasia, differences in inflam-
matory activity between the individual samples was
observed 16.6% (6/36) of the sample-sets. The highest
inflammatory activity was always observed in samples
obtained at the location with most severe histological
abnormality of that particular time point.
3.3 DNA ploidy
Biopsy specimens of four follow-up visits (ND n=3, LGD
n=1) of the cases and fourteen follow-up visits of the
controls (ND n=10, IND n=4) could not be graded due to
severity of inflammation or a limited amount of tissue.
DNA aneuploidy (DI >1.34) in the cases was detected in
28.2% (33/110) of the follow-up visits. A near-diploid (DI
1.06 to 1.34) and diploid (DI 0.96 to 1.05) DNA content
was seen respectively in 46.4% (51/110) and 25.5% (28/
110) of the follow-up visits. For the controls, DNA
aneuploidy was found in 2.2% (3/134) of the follow-up
visits, and a near-diploid and diploid DNA content was
observed in 3.0% (4/134) and 94.8% (127/134) of the
follow-up visits, respectively.
When the cases were subdivided by grade of neoplasia,
DNA aneuploidy was found in 50% (10/20) of the follow-
up visits with CRC versus 16.7% (1/6) in those with HGD,
62.5% (5/8) in those with LGD, 31.6% (6/19) in those with
IND, and 17.2% (10/58) in those with ND, while a near-
diploid DNA content was seen in 45.0% (9/20), 33.3% (2/6),
12.5% (1/8), 52.6% (10/19), and 50.0% (29/58), respectively
(Fig. 2a).
In 27.7% (10/36) sample-sets obtained from single
patients with neoplasia at a particular time point, differ-
ences in DI were seen between the individual biopsy
specimens. The DI was the highest at the most severe
histological abnormality present at that particular time
point. In the sample-sets, where biopsy specimens with
HGD and/or CRC were found together with specimens
without neoplasia (n=5, 3 sporadic lesions, 2 multifocal
lesions), an abnormal DNA content was detected in speci-
mens without neoplasia at a maximal distance of 65 cm
from the lesion.
Five years prior to the development of CRC, an
increase in the proportion of follow-up visits with DNA
aneuploidy was found for the cases from 18 to 43%. In
general, once DNA ploidy was positive it stayed positive
over time. When a DI ≥1.06 was used as determinant,
already ∼70% of cases were positive 10 years prior to
the ultimate diagnosis of CRC, and this proportion
remained stable over time. In the controls, the values
were <5%, and no increase in the proportion of follow-
up visits with an abnormal DNA content was seen over
time (Fig. 3a).
3.4 p53 expression
Biopsy specimens of four follow-up visits of the cases (ND n=
3, CRC n=1) and ten follow-up visits of controls (ND n=9,
IND n=1) could not be graded due to severity of
inflammation or a limited amount of tissue. p53 immunopo-
sitivity in the cases was found in 37.3% (41/110) of the
follow-up visits (Fig. 2b). By grade of neoplasia, these values
were 73.7% (14/19) of the follow-up visits with CRC, 66.7%
(4/6) with HGD, 55.6% (5/9) with LGD, 26.3% (5/19) with
IND, and 24.1% (14/58) with ND. For the controls, only
2.9% (4/138; IND 1/16 and ND 3/121) of the follow-up
visits were p53 positive.
In 16.6% (6/36) of the sample-sets obtained from
single patients with neoplasia at a particular time point,
differences in p53 immunopositivity were seen between
the different biopsy specimens. p53 immunopositivity
was found at the most severe histological abnormality
present at that particular time point. In the sample-sets,
where biopsy specimens with HGD and/or CRC were
found together with specimens without neoplasia (n=5),
p53 immunopositivity was detected in specimens without
neoplasia at a maximal distance of 55 cm from the lesion.
Prior to the development of CRC, an increase in the
proportion of follow-up visits with p53 immunopositivity
was seen in the cases from 10 to 75%. Once p53 was
positive it remained positive over time. The increase in p53
immunopositivity was predominant at the time close to the
development of CRC. In controls, p53 immunopositivity
was detected in <5%, and no increase in proportion was
detected over time (Fig. 3b).
When the p53 status of the cases was combined with
the DNA ploidy data, only 14.8% (16/108) of the follow-
up visits were p53 positive and had a DI >1.34
(aneuploid), in ten different patients, compared to none
of the controls (Fig. 2c). When DNA ploidy with a DI of
1.06 to 1.34 (near-diploid) was considered as positive,
13.8% (13/108) of the follow-up visits in the cases were
positive for both markers, in eight different patients,
compared to one (0.8%, 1/130) follow-up visit of one
control patient.
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3.5 Prognostic value of the biomarkers
To compare the prognostic value of an abnormal DNA
content, p53 immunopositivity and histological activity versus
LGD for predicting neoplastic progression in subgroups of
IBD patients, Cox regression with time dependent covariates
was performed. With adjustment for age, significant associ-
ations with progression to advanced neoplasia were found for
LGD, abnormal DNA ploidy, p53 immunopositivity, and
moderate and severe colitis (Table 2).
Considering DNA ploidy with a DI 1.06–1.34 (near-
diploid) over the length of surveillance as positive, a 4.7-
a
b
c
0
20
40
60
80
100
ND IND LGD HGD CRC ND IND LGD
(n=58) (n=19) (n=9) (n=6) (n=19) (n=121) (n=16) (n=1)
= p53 -
= p53 +
%
 
o
f f
o
llo
w
-
u
p 
vis
its
0
20
40
60
80
100
ND IND LGD HGD CRC ND IND LGD(n=58) (n=19) (n=8) (n=6) (n=20) (n=120) (n=13) (n=1)
= DI 0.96-1.05
= DI 1.06-1.34
= DI >1.34
%
 
o
f f
o
llo
w
-
u
p 
vis
its
Cases Controls
Cases Controls
Cases Controls
0
20
40
60
80
100
ND IND LGD HGD CRC ND IND LGD
(n=56) (n=19) (n=8) (n=6) (n=19) (n=116) (n=13) (n=1)
= DI 0.96-1.05 / p53 -
= DI 0.96-1.05 / p53 +
= DI 1.06-1.34 / p53 -
= DI 1.06-1.34 / p53 +
= DI >1.34 / p53 -
= DI >1.34 / p53 +
%
 
o
f f
o
llo
w-
u
p 
vis
its
 
Fig. 2 Prevalence of abnormal DNA content and p53 immunoposi-
tivity in different IBD subgroups. a Percentages of abnormal DNA
content determined by flow cytometry in different subgroups of
IBD patients. Biopsy specimens of four follow-up visits (ND n=3,
LGD n=1) of the cases and fourteen follow-up visits of the controls
(ND n=10, IND n=4) could not be graded due to severity of
inflammation or a limited amount of tissue. P-values from random
effect regression analyses for difference between the cases and
controls in abnormal DNA content are p=0.009 for DI 1.06–1.34
and p=0.0.07 for DI >1.35. In the ND-group the same analysis
revealed p-values of p=0.006 and p=0.03, respectively. b Percen-
tages of p53 immunopositivity determined by immunohistochemistry
in different subgroups of IBD patients. Biopsy specimens of four
follow-up visits of the cases (ND n=3, CRC n=1) and ten follow-up
visits of controls (ND n=9, IND n=1) could not be graded due to
severity of inflammation or a limited amount of tissue. p53
overexpression is defined as moderate and intense brown staining
in >15% of the nuclei. P-value from random effect regression
analyses for difference between the cases and controls in p53
immunopositivity is p=0.5. In the ND-group the p-value for p53
immunopositivity was p=0.6. c Percentages of abnormal DNA
content and p53 immunopositivity in different subgroups of IBD
patients. P-values from random effect regression analyses for
difference between the cases and controls in abnormal DNA content and
p53 immunopositivity is p=0.3 for DI 0.96–1.05/p53+, p=0.1 for DI
1.06–1.34/p53-, p=0.1 for DI 1.06–1.34/p53+, p=0.04 for DI >1.34/p53-
, p=1.0 for DI >1.34/p53+. In the ND-group these p-values were p=0.4,
p=0.2, p=0.2, p=0.03, p=1.0 respectively. DI 0.96–1.05 and p53- have
been used as reference conditions. ND, no dysplasia; LGD, low grade
dysplasia; HGD, high grade dysplasia; CRC, colorectal cancer
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fold increased risk for neoplastic progression was
calculated. When DNA ploidy marked as DI >1.34
(aneuploid) was used as criterion, the risk of advanced
neoplasia was 6.6-fold increased. For p53 immunoposi-
tivity, a 3.0-fold increased risk for advanced neoplasia
was observed over time. For mild, moderate and severe
colitis, the age adjusted analyses revealed respectively a
2.3, 4.1, and 3.4-fold increased risk for advanced
neoplasia. For LGD, the risk for neoplastic progression
was established at 5.5-fold.
When the risk values were adjusted for both age and
presence of LGD, abnormal DNA ploidy, p53 immunopo-
sitivity, and moderate and severe colitis remained statisti-
cally significant predictive of neoplasia (Table 2). The risks
for advanced neoplasia were established at 3.6-fold for a DI
1.06–1.34, 5.3-fold for a DI >1.34, 1.7-fold for p53
immunopositivity, and 4.0 and 4.7-fold for moderate and
severe colitis.
Adjustment for all confounders revealed significant
relationships between DNA ploidy status, p53 immunopo-
sitivity andmoderate colitis, and the risk for later development
of advanced neoplasia (Table 2). The increased risks for
advanced neoplasia was calculated at 4.3-fold for a DI 1.06–
1.34, and 4.8-fold for a DI >1.34. For p53 immunopositivity
and moderate colitis, the risk was established at 1.7 and 3.0-
fold, respectively.
4 Discussion
Many centers perform colonoscopic surveillance in patients
with longstanding IBD, but despite these programs, CRC
remains an important cause of IBD-related mortality [20].
Particularly for patients with PSC and/or extensive
colitis with a duration of >8 years, conventional
colonoscopic surveillance with random biopsy sampling
every 1–3 year seems to be insufficient [6, 23, 30].
Several recent studies have focused on the value of adding
specific biomarkers to predict the development of IBD-
related CRC [16, 22, 25, 34].
At present, DNA ploidy and p53 are recognized as
promising candidates for prediction of IBD-related CRC.
Their obvious advantage is that they are both diffusely
expressed and present at an early stage in the IBD related
dysplasia-carcinoma sequence (Fig. 2, and ref. [17, 18, 22,
26]). However, the relative risk of abnormal DNA ploidy
and p53 immunopositivity in developing IBD-related CRC
has never been calculated. In the present study, a case–
control study design based on our IBD surveillance
database was performed to determine the risk of advanced
neoplasia of both markers in subgroups of IBD patients.
Potential biases in the study population were avoided by
matching for age, gender, colitis characteristics, age of
onset, duration of the disease, interval of follow-up,
presence of PSC, and previous surgery.
In our study population, in age adjusted analyses
significant relationships were observed between develop-
ment of advanced neoplasia and prior presence of LGD
(HR5.5), abnormal DNA ploidy (DI 1.06–1.34, HR4.7, and
DI >1.34, HR6.6), and p53 immunopositivity (HR3.0) over
time. When histological results were taken into account, i.e.
the presence of LGD, both DNA ploidy and p53 immuno-
positivity maintained statistical significant predictors for
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Fig. 3 Fraction of biopsy specimens with abnormal DNA content/p53
immunopositivity over time prior to the development of colorectal
cancer (CRC). a Fraction of abnormal DNA content. = cases,
DI ≥1.06; = cases, DI >1.34; = controls, DI ≥1.06
and = controls, DI >1.34. b Fraction of p53 overexpression.
= cases; = controls. The numbers under each figure
represent the number of IBD patients at that time point. The symbols
at time point zero represent the fraction of patients at either time point
with progression (cases n=20) or at last follow-up visit without
progression (controls n=34)
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development of advanced neoplasia (Table 2). Moreover,
after adjustment for more confounders, abnormal DNA
ploidy and p53 immunopositivity remained statistically
significant predictive of neoplasia, with increasing risk for
abnormal DNA ploidy depending on higher DI levels
(Table 2).
Although risk stratification based on severity of histo-
logical signs of inflammation in IBD-related CRC was not
the primary goal of this paper, we observed a correlation
between severity of histological inflammation and increas-
ing risk of neoplasia (Table 2). Evaluation of surveillance
biopsy specimens showed that cases more often had
histological signs of moderate colitis compared to the
controls, in the years prior to the development of advanced
neoplasia (HR 3.0). This observation is in agreement with
recently published data [13, 31], and supports the concept
that severity of inflammation in IBD patients is a risk factor
for IBD-related neoplasia [13].
Despite the advantage of our case–control study design,
there are several potential limitations to this report. Firstly, all
patient material was tested retrospectively. Unfortunately, a
prospective trial analogous to our study will encounter large
difficulties and costs because of required patient numbers,
years of follow-up, and surveillance colonoscopies
needed [6, 7]. Secondly, our study was based on immuno-
histochemistry, which has the intrinsic shortcoming that the
amount of staining is not linearly related to the amount of
protein present, and may vary with the kit used.
Albeit most colonoscopies were performed during
remission of the disease, some biopsy specimens have been
taken when remission could not be achieved. The presence
of histological signs of inflammation, and the regional or
patchy presence of dysplasia, abnormal DNA ploidy and
p53 immunopositivity [16, 21] which may even change
over time [3, 24], might be a third putative drawback of the
study. However, we tried to minimize these problems by
using multiple biopsy specimens taken from different
locations of the colon, validated scoring systems and two
experts to evaluate histology and p53 immunopositivity. In
order to calculate the hazard ratios we had to assume that
the biopsy results at each location and time point accurately
represented the grade of neoplasia, DNA ploidy status and
p53 immunoreactivity in the colon at that interval.
Obviously, this may not be correct, but given the number
of specimens tested per patient, we expect that this bias was
minimal.
Although we studied patients with UC as well as CD,
no subdivision was made between the patient groups.
This decision to interpret all results in the same analysis
was based on the finding that no clear differences were
seen between histology, DNA ploidy status and p53
immunoreactivity within the two different patient groups
(data not shown).
Cox regression analysis with time-dependent covariates
and random effect regression analyses in the ND-group
revealed that patients positive for DNA ploidy and/or p53
are at high-risk of developing CRC. Therefore, extending
the conventional colonoscopic surveillance with DNA
ploidy and p53 could permit assigning IBD patients to
either a low-risk (negative for dysplasia, DNA ploidy and
p53), intermediate-risk (positive for dysplasia, DNA ploidy
or p53) or high-risk (positive for dysplasia and DNA
ploidy/p53) group. This refinement of risk stratification is
of interest, since it would allow to allocate the resources
more appropriate by reducing the number of unnecessary
endoscopies for patients at a low-risk of developing CRC,
while enabling more intensive surveillance endosocopies
for those at high-risk of developing CRC. The results of
this study suggest that the interval of colonoscopic
surveillance in low-risk patients can be deferred up to
Table 2 Prognostic value of LGD, abnormal DNA ploidy, p53 immunopositivity and inflammatory activity for neoplastic progression in high-
risk IBD patients according to Cox regression analysis with time-dependent covariates
Variable Adjusted for age Adjusted for age and LGD Adjusted for all other variables
HR (95%CI) p HR (95%CI) p HR (95%CI) p
LGD 5.5 (2.6–11.5) <0.0001 2.0 (0.8–4.9) 0.2
DNA ploidy, 1.06≤DI≤1.34a 4.7 (2.9–7.8) <0.0001 3.6 (2.2–5.9) <0.0001 4.3 (2.5–7.2) <0.0001
DNA ploidy, DI >1.34 6.6 (3.7–11.7) <0.0001 5.3 (3.3–8.3) <0.0001 4.8 (2.3–9.6) <0.0001
p53 immunopositivityb 3.0 (1.9–4.7) <0.0001 2.2 (1.3–3.7) 0.002 1.7 (1.0–3.1) 0.04
Mildly active inflammation 2.3 (0.9–5.3) 0.07 2.1 (0.8–5.4) 0.1 1.9 (0.7–4.9) 0.2
Moderately active inflammation 4.1 (1.8–9.1) 0.001 4.0 (1.7–9.6) 0.002 3.0 (1.2–7.2) 0.02
Severely active inflammation 3.4 (1.4–8.2) 0.005 4.7 (2.2–9.9) <0.0001 2.3 (0.9–5.9) 0.1
a DI, DNA index, calculated as ratio of the abnormal G0/G1 mean peak channel number to the normal diploid G0/G1 mean peak channel number
b p53 immunopositivity, defined as moderate and intense brown staining in >15% of the nuclei [14]
LGD, low grade dysplasia
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5 years. This has to be evaluated in future prospective
studies. The surveillance in intermediate- and high-risk
patients should however be intensified to every year and
every 3 months, respectively. In the patients at risk, novel
endoscopy techniques, such as highmagnification endoscopy,
chromoendoscopy, narrow band imaging, or autofluorescence
endoscopy may enhance the detection of suspicious lesions
[12, 27, 28, 35].
In conclusion, the data from our study support the
notion that the use of DNA ploidy and p53 enhance the
sensitivity of correctly selecting patients at an increased
risk of IBD-related CRC development. Given the
retrospective nature of our study and its limited power,
the potential utility of DNA ploidy and p53 immunohis-
tochemistry into clinical management of patients with
longstanding IBD warrants further investigation.
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